OUR TEAM

James Yoh, PhD

President

James W. Yoh, Ph.D. graduated from the Fu-Jen Catholic University, Department of Physics, in 1969. After one year of military service, Dr. Yoh went to the United States for his advanced study, receiving a doctoral degree in Nuclear Physics from the University of Notre Dame in 1975. Dr. Yoh received his post-doctoral training at the Ohio State University in Columbus, Ohio. Dr. Yoh founded Galaxy Scientific Corporation in 1988, a leading innovative high technology entity in the Defense and Aviation industry in the United States. Dr. Yoh is an active community supporter who has been appointed by four different Governors of New Jersey to serve as a Trustee for The Richard Stockton College of New Jersey and has served as past Chair of the Board of Trustees for the College.


Hai-Lung Dai, PhD

Chair, Board of Directors
Chair, Scientific Advisory Board

Dai received his BS from National Taiwan University and PhD from UC Berkeley and did his postdoctoral research at MIT. From 1984-2006, he was at the University of Pennsylvania having served as the Chairman of the Department of Chemistry and the Hirschmann-Makineni Professor. Since 2007, he has been at Temple University, first as the Dean of the College of Science and Technology and later Provost and Executive Vice President, and Vice President for International Affairs. He is currently the Laura H. Carnell Professor of Chemistry and Director of Institute for Membranes and Interfaces. Dr. Dai is an active, funded researcher in physical chemistry specializing in laser spectroscopy, molecular dynamics, surface and colloidal chemistry, and biophysical chemistry. He has published >220 articles, delivered over 390 invited lectures and received numerous honors including a Guggenheim Fellowship, the Lippincott Award in Molecular Spectroscopy from the Optical Society of America, and the Langmuir Lecturer Award from the American Chemical Society. Dai has served in advisory roles for numerous government agencies, professional societies, civic organizations, universities and research institutions worldwide.


Solomon Luo, MD, FACS

Secretary and Treasurer, Board of Directors

Solomon Luo, MD, FACS, a practicing Ophthalmologist specializes in clinical and academic ophthalmic practice. The Founding Father, CEO and President of Progressive Vision Institute. Dr. Luo received his BS degree in Biology from Fu-Jen Catholic university, MS and MD degree from University of Texas. Previously a medical board member of Pennsylvania, and currently, a trustee board member and chairman of the Health Enterprise committee of Temple University, clinical professor and health system board member. Dr. Luo is also involved in many other Ophthalmology and cancer researches, currently the chairman of Lynthera inc., Chairman of Halcyon Diagnosis and Halcyon Therapeutic inc., Board member of Continuous Precision Medicine, a company which fighting the Drug/Opioid crisis. Co-founder and chairman of Primal Space System/Interactivity.


Barry Arkles, PhD

Board of Directors

Dr. Barry Arkles has a record of accomplishment in applied materials science, surface chemistry and biotechnology both from the innovation and managerial perspective that can be noted in contributions to a variety of applications including thermoplastic composites, the NASA Space Shuttle, Contact Lenses, Interlayer Dielectrics and Metallization used in integrated semiconductor devices, and Gene Chips for DNA array analysis. Today the companies that he founded or cofounded generate nearly $1,000,000,000 in annual revenue: LNP Engineering Thermoplastics, Petrarch Systems Inc., and Gelest Inc, now part of SABIC Basic Industries, Evonik, and Mitsubishi Chemical, Inc, respectively. He has published over 150 technical articles and has been granted over 100 patents. He has been elected to the National Academy of Engineers and elected as a Fellow of the Royal Society of Chemistry. He has received numerous awards including the John Scott Medal, ACS Kipping Award in Silicon Chemistry, the R&D 100 Award for contributions to semiconductors.


Charles Chen, DSc h.c.

Vice Chair, Board of Directors

Chen is a world leader and entrepreneur in the biotech industry with more than four decades of experiences and accomplishments in developing, producing, and implementing forefront vaccine and diagnostic technologies. He is the founder and CEO of the publicly listed Medigen Vaccine Biologics Corp. and the privately owned Schweitzer Biotech Co. of Taiwan. He received his BS degree in psychology from National Taiwan University in 1974. He has since self-taught to become an expert in vaccine and diagnostic technologies for human and animal diseases. He has coauthored dozens of scholarly papers in top journals such as The Lancet and Clinical Infectious Diseases. In 2015, he was appointed Distinguished Adjunct Professor of Biotechnology in the Biology Department of Temple University. He was a Chair Professor of Industry-Academia Collaboration at National Yangming Chiaotung University, one of the top universities in Taiwan. In 2023, he honored with an Honorary Doctoral Degree in Science from Temple University.


James Ting

James back slashed his career and joined Bio-technology business in 2017, after 20+ years in Banking Sectors. Prior to get involved in bio-technology, James was senior VP and the private banking business head of HSBC Taiwan. James was well known in the banking business through his innovative and execution capabilities. During 2008 to 2012, he worked in Great China areas (ie, China, Hong Kong and Taiwan) and hold various positions, This experience allowed James see through the vast changes of China. During the COVID 19 pandemic, James lead the team to develop diagnostics which were approved by the health authority for emergency use in Taiwan and EC. James obtained MBA degree from Austin, University of Texas in 1992.


Joseph Katter

Executive Director

Joseph Katter has over 20 years of experience in the field of public-private financing for biomedical research and biotech commercialization. As Founding Principal of the Capital Group, a US-based Project Finance Consultancy, he has managed substantial public funding and private investment in early stage biomed-biotech commercialization including incubation/acceleration platforms and dedicated venture funds to support early stage company formation in this vertical. He holds a BA in Economics from Villanova University (Philadelphia, PA), MA in Applied and Development Economics from the American University (Washington, DC) and an Adjunct Professorship at Temple University’s College of Science & Technology. He is a Fellow of the Royal Society for Encouragement of the Arts, Manufactures and Commerce (RSA).


Jianqiang Ma, PhD

Senior Scientist

Dr. Ma received his MS in Chemistry at the University of Pennsylvania and his PhD in Chemistry at Temple University. He completed two post-doctoral trainings from the University of Pennsylvania and Columbia University. Dr. Ma is currently an Assistant Professor at Temple University Medical School. Dr. Ma's research expertise includes laser spectroscopy and microscopy, noble metal and semiconductor nanomaterials, molecular biophysics/biochemistry. Dr. Ma has published more than 20 research articles in top scientific journals. Dr. Ma is responsible for DiaVac's development of molecular diagnostic products; and regulatory validation process of animal biologic products with USDA.

OUR PARTNERS

Schweitzer Biotech Company

SBC is a dynamic and innovative company dedicated to developing new solutions that contribute to the wellbeing of humans, animals, and the environment. With more than 40 years of experience in the development, production, and registration of vaccines for animal diseases, SBC takes pride in providing its global customers with breakthrough technologies to accomplish their goals and strengthen their market position. SBC has collaborated with the world's top 10 animal health companies and built an excellent reputation in animal disease prevention and control. In recent years, SBC has diversified its business activities to animal disease diagnostics, human vaccines, dietary supplements, and environmentally friendly technologies.


Medigen Vaccine Biologics Corp.

MVC is a Taiwan-based biopharmaceutical company focusing on the development and mass production of vaccines and biologics. They have PIC/S GMP certified cell culture commercial mass production capabilities, and target global and regional infectious diseases to develop novel vaccines and affordable biosimilar drugs via international alliances.


SpectroChip

Based on patented miniaturized spectrometer technologies, SpectroChip develops compact and multifunctional spectroscopic detection instruments for next generation medical diagnostic devices.


Temple Genetics Lab (Contractor)

A CLIA-certified laboratory at Temple Medical School by the Centers for Medicare and Medicaid Services.


Learn About Our Diagnostic Technologies and Vaccines.